A one-pot process for preparing molnupiravir from cytidine was developed. The advantages
of this synthesis were as follows:(1) The presence of N, N-dimethylformamide dimethyl …

Coronaviruses are a group of enveloped viruses with non-segmented, single-stranded, and
positive-sense RNA genomes. It belongs to the 'Coronaviridae family', responsible for …

MK-7845 was designed as a 3C-like protease inhibitor for the treatment of COVID-19. To
enable a rapid kilo-scale delivery of MK-7845 to accelerate its First-in-Human studies, we …

A four step synthetic process has been developed for the synthesis of orally active
ribonucleoside molnupiravir (MK-4482 & EIDDD-2801), starting from a readily available d …

Molnupiravir, the prodrug for β-D-N4-hydroxycytidine (NHC), is marketed by Merck as
Lagevrio™ against mild–moderate COVID-19, under FDA emergency use authorization. It is …

The constant demand for sustainable approaches to pharmaceutical synthesis has thrived
the enzyme catalysis (biocatalysis) field. The most sought‐after features like high specificity …

Due to the need for molnupiravir (EIDD-2801, MK-4482) anti-COVID-19 agent, in the present
report, we have systematically investigated the effect of different solvents, acids (as catalyst) …

Nucleoside analogues are effective antiviral agents, and the continuous emergence of
pathogenic viruses demands the development of novel and structurally diverse analogues …

An enzymatic approach for the synthesis of Molnupiravir has been developed using
immobilized lipase as a biocatalyst. This method involves a concise process of the …

Our research addresses the shift towards continuous manufacturing in the pharmaceutical
industry, focusing on optimizing chromatographic separation for the synthesis of …